Treating to Reduce Albuminuria and Normalize Hemodynamic Function in Focal ScLerosis With dApagliflozin Trial Effects: "The TRANSLATE Study"

Trial Profile

Treating to Reduce Albuminuria and Normalize Hemodynamic Function in Focal ScLerosis With dApagliflozin Trial Effects: "The TRANSLATE Study"

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 27 May 2017

At a glance

  • Drugs Dapagliflozin (Primary)
  • Indications Focal segmental glomerulosclerosis
  • Focus Pharmacodynamics
  • Acronyms TRANSLATE
  • Most Recent Events

    • 28 Oct 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top